The effect of saffron on patients with chemotherapy-induced neuropathy

The effect of Crocus sativus L. (saffron) on patients with chemotherapy-induced neuropathy; A clinical trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180119038433N1

Enrollment

Registered

2018-12-28

Start date

2018-12-22

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-induced nephropathy. Drug-induced polyneuropathy

Interventions

Intervention 1: Patients with chemotherapy-induced neuropathy receiving a 15 mg tablet of saffron (crocin) daily up to 3 months (produced by Mashhad University of Medical Sciences). Intervention 2: Co

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chemotherapy-induced neuropathy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of neuropathy (based on items in the questionnaire) of patients receiving chemotherapy. Timepoint: Evaluation of neuropathy in patients before administration of medication is between the administration period (day 45 after the intervention, ie the administration of the first dose, placebo and positive control) and after treatment (up to 1 month after the last administration of the intervention). Method of measurement: Nerve conduction velocity test as well as questionnaire.	—

Measure

Time frame

Severity of neuropathy (based on items in the questionnaire) of patients receiving chemotherapy. Timepoint: Evaluation of neuropathy in patients before administration of medication is between the administration period (day 45 after the intervention, ie the administration of the first dose, placebo and positive control) and after treatment (up to 1 month after the last administration of the intervention). Method of measurement: Nerve conduction velocity test as well as questionnaire.

—

Secondary

Measure	Time frame
Life quality Score. Timepoint: Prior to prescribing, between the administration period (45 days after the intervention, ie the administration of the first dose, placebo and positive control) and after treatment (up to 1 month after the last administration of the interventions). Method of measurement: Short questionnaire 12 questions (SF12).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHooman bozorgi

Semnan University of Medical Sciences

hoomanbozorgi@semums.ac.ir+98 23 3142 2001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026